Rigel(RIGL) - 2023 Q3 - Quarterly Report

Financial Performance - For the nine months ended September 30, 2023, net product sales of TAVALISSE were $68.1 million, a 26% increase compared to the same period in 2022[105]. - Net product sales for the nine months ended September 30, 2023, rose by 39% to$ 74,755,000 from $53,935,000 in the prior year[186]. - Product sales for the three months ended September 30, 2023, increased by 41% to$ 27,129,000 compared to $19,188,000 in the same period of 2022[186]. - TAVALISSE net product sales increased by$ 5.3 million or 27% in Q3 2023 and $14.1 million or 26% in the nine months of 2023 compared to the same periods in 2022[186]. - REZLIDHIA generated net product sales of$ 2.7 million and $6.7 million for the three and nine months ended September 30, 2023, respectively[186]. - Interest income increased to$ 1.6 million for the nine months ended September 30, 2023, compared to $0.3 million in the same period of 2022, reflecting a rise of approximately 533%[214]. - Interest expense rose to$ 5.0 million for the nine months ended September 30, 2023, from $2.6 million in the same period of 2022, an increase of approximately 92%[215]. Research and Development - The Phase 1b trial of R289 is expected to enroll approximately 22 patients, with preliminary results anticipated by mid-year 2024[109]. - Lilly has initiated a Phase 2a trial for R552, which plans to enroll 100 patients globally, focusing on moderately to severely active rheumatoid arthritis[110]. - The primary endpoint of the FOCUS Phase 3 clinical trial for fostamatinib in hospitalized COVID-19 patients was met after correcting a statistical error, showing lower mean days on oxygen compared to placebo (4.8 vs. 7.6 days, p=0.0136)[112]. - The NIH/NHLBI recommended ceasing enrollment in the fostamatinib study arm of the ACTIV-4 Host Tissue Trial due to low likelihood of benefit for primary outcomes[115]. - The Phase 2 trial of olutasidenib showed an overall response rate (ORR) of 46% and a median overall survival of 10.5 months for patients with CR/CRh[143]. - The Phase 2 trial data for fostamatinib in wAIHA was published in the American Journal of Hematology, highlighting its potential to increase hemoglobin levels in nearly half of the patients[170]. - The FORWARD Phase 3 clinical trial for wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population[174]. Product Development and Commercialization - The company paid an upfront fee of$ 2.0 million for the in-licensing of olutasidenib, with potential additional payments of up to $67.5 million upon achieving specified development and regulatory milestones[107]. - The commercialization agreement with Grifols includes an upfront cash payment of$ 30 million and potential regulatory and commercial milestones of up to $297.5 million[131]. - The agreement with Medison for Canada and Israel includes an upfront payment of$ 5 million and potential milestones of approximately $35 million[135]. - REZLIDHIA demonstrated a complete remission (CR) plus complete remission with partial hematologic recovery (CRh) rate of 35% in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with mIDH1 mutations[140]. - The FDA approved REZLIDHIA for R/R AML with IDH1 mutation on December 1, 2022, and commercialization began on December 22, 2022[141]. - Commercial activities for REZLIDHIA will focus on healthcare providers managing R/R AML patients, with plans for collaborations outside the US[153]. Financial Position and Cash Flow - Cash and cash equivalents as of September 30, 2023, were approximately$ 62.4 million, up from $58.2 million as of December 31, 2022[221]. - Net cash provided by operating activities for the nine months ended September 30, 2023, was$ 0.5 million, a significant recovery from a net cash used of $51.8 million in the same period of 2022[222]. - Net cash provided by investing activities for the nine months ended September 30, 2023 was$ 17.4 million, a decrease from $54.0 million in the same period of 2022[223]. - Net cash provided by financing activities for the nine months ended September 30, 2023 was$ 20.0 million from term loan financing, compared to $19.5 million in the same period of 2022[224]. - The company expects to incur significant selling, general, and administrative expenses as it expands its commercial activities[213]. - The company may need to raise additional funds through public or private offerings, which could lead to substantial dilution of shareholders' ownership interests[233]. Regulatory and Market Considerations - The competitive landscape for TAVALISSE includes existing therapies and potential generic versions that could impact revenue[127]. - The competitive landscape includes TIBSOVO® (ivosidenib), which is also approved for patients with IDH1 mutation, highlighting the need for effective differentiation in marketing strategies[152]. - The company retains global rights to fostamatinib outside of specific territories under various license agreements[129]. - The company has not sold any shares of common stock under the Open Market Sale Agreement, which allows for sales up to$ 250.0 million[229].